Author + information
- Received January 19, 2016
- Revision received April 25, 2016
- Accepted June 2, 2016
- Published online February 6, 2017.
- Abdallah El Sabbagh, MDa,
- Mohammed A. Al-Hijji, MDa,
- Jeremy J. Thaden, MDa,
- Sorin V. Pislaru, MD, PhDa,
- Cristina Pislaru, MDa,
- Patricia A. Pellikka, MDa,
- Adelaide M. Arruda-Olson, MDa,
- Martha Grogan, MDa,
- Kevin L. Greason, MDb,
- Joseph J. Maleszewski, MDa,c,
- Kyle W. Klarich, MDa and
- Vuyisile T. Nkomo, MD, MPHa,∗ ()
- aDivision of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota
- bDivision of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota
- cDivision of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota
- ↵∗Address for correspondence:
Dr. Vuyisile T. Nkomo, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
Cardiac myxoma is the most common primary cardiac neoplasm in adults. They most commonly arise within the left atrium, but may arise from other cardiac chambers, rarely from the valves. Histologically, cardiac myxomas consist of lepidic (“myxoma”) cells within a myxoid stroma. They can be of variable size, shape, and mobility. Some have a smooth surface, and others are more villiform. The latter tends to associate more with thromboembolic phenomenon, either from friable tumor or adherent surface thrombus forming on the frond-like areas. Intratumoral hemorrhage, owing to the vascular nature of the lesions, and calcification are common. Clinical manifestations of cardiac myxoma are protean and generally nonspecific, often resulting in delayed treatment of prompt surgical resection. Recognition of cardiac myxoma, and discrimination from other cardiac masses, is necessary for accurate treatment and follow-up management. Our aim is to provide an imaging-based description of the varied presentations of cardiac myxoma (Figures 1, 2, 3, 4, 5, and 6).
The clinical presentations of cardiac myxoma are largely determined by the size, architecture, and location of the tumor. Although cardiac myxomas are histologically benign, the manifestations (e.g., embolism) can be serious. Multimodality imaging is pivotal in diagnosing atrial myxomas. Nevertheless, gross and histopathologic evaluation are necessary to confirm the diagnosis.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received January 19, 2016.
- Revision received April 25, 2016.
- Accepted June 2, 2016.
- American College of Cardiology Foundation